| Target Professions: | DO, MD, Nurse Practitioner, Physician Associate/Assistant |
| Target Specialties: | Allergy and Immunology |
| Credits Available: | 4.50 AMA PRA Category 1 Credits™ |
This peer-to-peer, multi-specialty program helps clinicians explore the evolving role of biologics in chronic rhinosinusitis with nasal polyps (CRSwNP). Through case-based modules, case challenges, and live group discussions, learners will identify candidates, sequence biologics with surgery, and strengthen cross-specialty collaboration to improve patient outcomes.
Test your baseline knowledge of CRSwNP management. Explore clinical scenarios that assess your approach to identifying biologic candidates, sequencing surgery and biologics, and coordinating care with allergy/immunology.
Learn how to identify CRSwNP patients who may benefit from biologics by evaluating type 2 inflammation, recurrence patterns, and comorbidities that signal high risk and guide therapy selection.
Learn how to sequence biologics and surgery in CRSwNP, including criteria for biologic candidacy, how to assess treatment response, and when to combine or transition therapies based on clinical guidelines and real-world data.
Enhance coordination between ENT and allergy in CRSwNP care. Learn when to involve allergy, how to communicate effectively across specialties, and how to align treatment plans for patients receiving or being considered for biologics.
Apply what you’ve learned to real-world CRSwNP cases. Assess your ability to identify biologic candidates, guide treatment decisions, and coordinate care with allergy/immunology for optimal outcomes.
This Live Group Discussion will focus on a case of a 46-year-old woman with newly diagnosed bilateral CRSwNP confirmed on endoscopy. We will also address any questions you may have regarding the baseline and final assessments and the self-study modules.
Meet Jackie, who is 5 months post-FESS, has recurrent CRSwNP, uncontrolled asthma, and elevated eosinophils/IgE. She lacks allergy care, EMR access is limited, and dupilumab was denied due to “insufficient documentation.”
Meet Ike, who is 2 weeks post-FESS with severe recurrent CRSwNP and asthma, and needs a biologic. You face barriers: allergy wait times, no clear protocols, outdated PA templates, and uncertainty around monitoring and long-term care.
Considering the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with CRSwNP.
This Live Group Discussion will review a case of a 50-year-old man with severe CRSwNP, moderate persistent asthma, and a recent diagnosis of eosinophilic esophagitis (EoE). We will also review your submissions on the Patient Case Challenge and Action Plans.
